Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
EGL Genetic Diagnostics, |
RCV000382340 | SCV000331273 | pathogenic | not provided | 2016-12-06 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000535509 | SCV000649663 | pathogenic | Qualitative or quantitative defects of dysferlin | 2019-09-06 | criteria provided, single submitter | clinical testing | This sequence change deletes 2 nucleotide and inserts 2 nucleotides in exon 32 of the DYSF mRNA (c.3444_3445delinsAA). This creates a premature translational stop signal (p.Tyr1148*) and is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been reported several times in the literature in either the homozygous or compound heterozygous state with a second DYSF variant in individuals affected with Miyoshi myopathy, distal myopathy, limb-girdle muscular dystrophy, and dysferlinopathy (PMID: 15469449, 19528035, 25493284, 27066573, 27602406). This variant is also known as 3817 8TG>AA in the literature. ClinVar contains an entry for this variant (Variation ID: 94305). Loss-of-function variants in DYSF are known to be pathogenic (PMID: 17698709, 20301480). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000763089 | SCV000893616 | pathogenic | Miyoshi muscular dystrophy 1; Autosomal recessive limb-girdle muscular dystrophy type 2B; Myopathy, distal, with anterior tibial onset | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000984168 | SCV001132181 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2018-02-01 | no assertion criteria provided | clinical testing |